Characteristics and Related Factors of Recurrent Epithelial Ovarian Carcinoma:61 Cases Report

燕鑫,陈春玲,张岩,廖秦平

DOI: https://doi.org/10.3969/j.issn.1672-1861.2004.03.006

2004-01-01

Abstract:Objective To analyze the possible factors influencing the recurrence of epithelial ovarian carcinoma and the therapies. Methods The clinic-pathological features of 171 patients with epithelial ovarian carcinoma, admitted during 1994 and 2002, were analyzed retrospectively. Among them, 61 cases with recurrence were compared with non-recurrence. Results Sixty-one out of the 171 ovarian carcinoma recurred(35 7%). The recurrent rate of cases complicated with breast cancer or other gynecological cancer was 45 5%, while with the familial history of gynecological malignant tumour was 100%. The recurrent rate of poor differentiated cancer was 47 2%,which was significantly higher than that of 21 1% in middle or well differentiated ( P 0 05). According to the FIGO criteria (1988) the recurrent rate of stageⅠ, Ⅱ (15 2%) was significantly lower than that of stage Ⅲ, Ⅳ(48 5%)( P 0 05). In cases with 2cm residual lesion, the recurrent rate (54 5%) was significantly higher than those with ≤2cm residual lesion (32 9%) ( P 0 05). The recurrent rate was lower in the patients treated with the completely chemotherapy (29 6%) than without(49 1%)( P 0 05). The recurrence had no relationships with the pregnancy, delivery histories, pathologic type, peritoneal cytology and whether undergone the lymphadenectomy. There was 39 3% recurrent cases underwent the compositive therapy including the second cytoreductive surgery, and their survival time was longer than that without the second cytoreductive surgery ( P 0 05). Conclusions Epithelial ovarian carcinoma relapse mostly within 3 years after initiative therapy. The most common recurrent sites are pelvic and peritoneal cavity and lung. Certain relationship is found between the recurrence and complication of breast cancer or other gynecological cancer, family history of gynecological malignant tumor, clinical stage, histological differentiation, postoperative residual volume and sufficient courses of regular chemotherapy. The compositive therapy including the second cytoreductive surgery should be conducted for the recurrent cases.